S-methyl-L-Cysteine

S-methyl-L-Cysteine is a derivative of cysteine that has been found in A. sativum and has diverse biological activities.^1,2,3,4,5 It is a substrate for methionine sulfoxide reductase A (MSRA) and decreases locomotor deficits induced by overexpression of human α-synuclein in a reactive climbing assay in a Drosophila model of Parkinson’s disease.⁶ S-methyl-L-Cysteine prevents exogenous cholesterol-induced increases in total cholesterol levels in serum and liver in rats with dysregulated cholesterol metabolism induced by propylthiouracil (Item No. 14069).³ It decreases plasma glucose, insulin, malondialdehyde (MDA), and TNF-α levels as well as increases glutathione (GSH) levels in rats fed a high-fructose diet when administered at a dose of 100 mg/kg.⁴ S-methyl-L-Cysteine (100 mg/kg, p.o.) reduces the number and area of hepatocellular foci containing the placental form of glutathione S-transferase (GST-P) in a rat model of diethylnitrosamine-induced hepatocarcinogenesis.⁵

WARNING This product is not for human or veterinary use.

1. Muoio, R., Casoria, P., and Menale, B. A comparative study of sulphur content of some Allium L. species. Econ. Bot. 58(2), 227-230 (2004).

2. Wassef, R., Haenold, R., Hansel, A., et al. Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson’s-like symptoms. J. Neurosci. 27(47), 12808-12816 (2007).

3. Hasimun, P., Sukandar, E.Y., Adnyana, I.K., et al. Synergistic effect of curcuminoid and s-methyl cysteine in regulation of cholesterol homeostasis. Int. J. Pharm. 7(2), 268-272 (2011).

4. Thomas, S., Senthilkumar, G.P., Sivaraman, K., et al. Effect of s-methyl-L-cysteine on oxidative stress, inflammation and insulin resistance in male wistar rats fed with high fructose diet. Iran. J. Med. Sci. 40(1), 45-50 (2015).

5. Fukushima, S., Takada, N., Wanibuchi, H., et al. Suppression of chemical carcinogenesis by water-soluble organosulfur compounds. J. Nutr. 131(3s), 1049S-1053S (2001).

6. Rosi, S., Pert, C.B., Ruff, M.R., et al. Chemokine receptor 5 antagonist D-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer’s disease. Neuroscience 134(2), 671-676 (2005).